{"disease":{"id":"relapsed-or-refractory-multiple-myeloma-rrmm","name":"relapsed or refractory multiple myeloma rrmm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07222761","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":915,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06615479","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT06484829","title":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT04824794","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT06103838","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06876142","title":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04776018","title":"A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06961669","title":"Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT07003568","title":"Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07003555","title":"Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}